Tag Archives: REACH

September 2007 Br J Cardiol 2007;14:190

REACHing for new heights in disease management

Deepak L Bhatt, P Gabriel Steg

Abstract

In this larger context, the international Reduction of Atherothrombosis for Continued Health (REACH) Registry was launched in order to study outcomes of atherothrombotic disease, risk factors for atherothrombosis, and also current treatment patterns. Already, the REACH Registry has provided insights at a global level.1 For example, under-treatment of common risk factors such as hypertension, hyperlipidaemia, and diabetes was observed in all regions included in the REACH Registry. Obesity, including morbid obesity, was highly prevalent. Multivascular disease – atherothrombosis affecting more than one arterial territory – was present in app

| Full text

September 2007 Br J Cardiol 2007;14:215-218

One-year data from the UK arm of the REACH Registry

Jonathan M Morrell, George C Kassianos

Abstract

As with the global results, there was a high use of evidence-based therapies in the UK patients. Despite this, the combined incidence of cardiovascular events at one year (cardiovascular death, myocardial infarction, stroke) was high at 4.82%, 4.46% and 4.35% respectively for peripheral arterial disease (PAD), cerebrovascular disease (CVD) and coronary artery disease (CAD). These figures increase markedly when hospitalisations are taken into account, particularly in patients with PAD (18.54%) compared with CVD (8.29%) and CAD (10.07%). Cardiovascular event rates increased significantly with the number of symptomatic locations (p=0.0043), incr

| Full text

September 2007 Br J Cardiol 2007;14(Suppl 3):S2-S16